Search results: (10000)
News Sports in People with Hemophilia – Possible and Safe
Active involvement in sports and an active lifestyle are important aspects of daily functioning for people with hemophilia. Modern treatment of this disease, including the prophylactic administration of concentrates of the missing coagulation factor, has led to an increase in the number of very active patients. Numerous studies have confirmed that they are as physically active as the general population, although some emphasize that this is more relevant to children and young people. Therefore, the work of Dutch and Swedish authors focused on examining the relationship between age and physical activity in hemophiliacs, especially with regard to more intensive and riskier sports.
News Analysis of Data from the EMPEROR-Preserved Study Revealed Whether Blood Pressure Affects the Effectiveness of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction
Hypertension is among the most common etiological factors of heart failure with preserved ejection fraction (HFpEF), where pressure overload of the left ventricle leads to its eccentric hypertrophy and diastolic dysfunction. According to recent study results, empagliflozin significantly reduces the risk of cardiovascular (CV) complications in patients with HFpEF. The EMPEROR-Preserved sub-analysis further examined the impact of baseline systolic blood pressure (sBP) on treatment outcomes and patient prognosis.
News Natural Doesn’t Always Mean Better – How to Deal with the Appeal to Nature in the Doctor’s Office
"Herbs rather than chemicals." Doctors are hearing similar statements more and more often. This attitude reflects the so-called appeal to nature – a logical fallacy based on the assumption that natural means better and safer. In academic literature, this type of thinking is more broadly referred to as the naturalistic fallacy. Such reasoning significantly influences not only patients’ decisions but often also those of healthcare professionals themselves.
News Atectura® and Enerzair® from May 1, 2021 with Health Insurance Coverage
The fixed combination of indacaterol acetate (LABA) and mometasone furoate (ICS) Atectura® and the fixed triple combination, which in addition to these two substances also includes glycopyrronium bromide (LAMA), Enerzair® for maintenance inhalation treatment of bronchial asthma, approved in the EU last year, have established health insurance coverage in the Czech Republic from May 1, 2021. We bring a summary of the conditions for reimbursement.
News Ivabradine and/or Sacubitril/Valsartan in the Treatment of Heart Failure with Reduced Ejection Fraction
Ivabradine and sacubitril/valsartan are used in the second line of therapy for heart failure with reduced ejection fraction (HFrEF). The aim of the study presented below was to evaluate the synergistic effect of these modern medications.
News Asthma and Prognosis of Patients with COVID-19
The impact of asthma, its severity, and treatment on the prognosis of patients infected with the SARS-CoV-2 coronavirus was examined in an observational study published this spring.
News Efficacy and Safety of Enoxaparin as Bridging Anticoagulant Therapy After Ventricular Assist Device Implantation
The implantation of a ventricular assist device has become an increasingly common method in the treatment of end-stage heart failure in recent years. The implantation of the device necessitates anticoagulant therapy. In the long term, warfarin is most often used according to guidelines, but there are no clear recommendations for early postoperative anticoagulant therapy. The aim of a clinical study published last year was to evaluate the efficacy and safety of enoxaparin as bridging anticoagulant therapy after device implantation within a 3-month postoperative period.
News Recommendations for Lipid Administration in Patients on Home Parenteral Therapy
Home parenteral therapy is an important part of treatment for patients with chronic intestinal failure who cannot achieve adequate nutrition through enteral feeding. An integral component of this therapy is lipid emulsion, which provides a source of energy and essential fatty acids. However, long-term administration of lipid emulsion may be associated with liver damage. According to available studies, the risk can be reduced by adjusting the dosage of lipid emulsion and preferring emulsions without soybean oil.
News No deficiency of essential fatty acids in home parenteral nutrition
A Dutch-British study, the results of which were published in the Journal of Parenteral and Enteral Nutrition, addressed the issue of potential deficiency of essential fatty acids in patients using home parenteral nutrition.
News Does Administration of Saline Make a Crucial Difference Compared to Balanced Crystalloids in Critically Ill Patients?
A study published in the New England Journal of Medicine provided data on mortality and deterioration of renal function in adult patients in intensive care units, depending on whether they received saline or balanced crystalloid solutions for fluid replacement.
News Nutritional Therapy for Critically Ill Patients in the ICU – Current Recommendations
Critically ill patients hospitalized in the intensive care unit (ICU) require nutritional support to maintain adequate energy intake. Only by doing so can their clinical condition be prevented from worsening. Therefore, we summarize the current recommendations regarding nutritional therapy as part of care in the ICU in the following text.
News How and with What the National Registry of Primary Immunodeficiencies Benefits Specialists and Patients
Primary immunodeficiencies constitute a very heterogeneous group of congenital diseases. They affect both specific and nonspecific immunity and are classified accordingly. The care for patients with antibody production disorders and hereditary angioedema (HAE) is economically the most demanding and relatively specific. Can a specialized registry help improve this care?
News From Hell to the Light at the End of the Tunnel – A Task for Eletriptan
In recent months, under the spotlight of new biological treatments, the focus has been predominantly on the prophylactic treatment of migraines. However, we should not forget about acute therapy. In this indication, the pharmacological group of triptans is dominant. So, does eletriptan reliably stop the hell named a migraine attack? And is the response to this drug consistent?
News Brentuximab Vedotin as Another Therapeutic Option in Cutaneous T-Cell Lymphoma
Current systemic treatment for patients with cutaneous T-cell lymphoma (CTCL) unfortunately has limited efficacy, achieving low response rates and short-lasting remissions. Moreover, there is no curative therapy modality for advanced stages of CTCL. However, the results of the recently concluded ALCANZA clinical trial indicate the potential of brentuximab vedotin in this indication.
News Current Recommendations of the Expert Panel on the Management of von Willebrand Disease
Von Willebrand disease (vWD) is a common congenital bleeding disorder. The care of patients with vWD involves significant variability due to bleeding manifestations and treatment options. The new recommendations from 2021 regarding the care of people with vWD are evidence-based and supported by the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation USA (NHF), and the World Federation of Hemophilia (WFH). We bring you a concise summary of the key points.